Media headlines about Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) have been trending somewhat positive recently, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Trillium Therapeutics earned a news impact score of 0.22 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 44.4774414191001 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Trillium Therapeutics (NASDAQ:TRIL) traded up 2.97% during mid-day trading on Wednesday, hitting $5.20. 118,145 shares of the stock were exchanged. The firm’s market capitalization is $56.13 million. The company’s 50-day moving average price is $4.58 and its 200 day moving average price is $5.31. Trillium Therapeutics has a 52 week low of $4.15 and a 52 week high of $17.70.
Several research firms have issued reports on TRIL. HC Wainwright set a $7.00 price target on shares of Trillium Therapeutics and gave the stock a “buy” rating in a report on Monday, August 14th. Cowen and Company reaffirmed a “buy” rating on shares of Trillium Therapeutics in a report on Wednesday, July 5th. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and issued a $18.00 price target on shares of Trillium Therapeutics in a report on Friday, June 9th. Finally, Zacks Investment Research cut shares of Trillium Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $14.95.
About Trillium Therapeutics
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companys lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.
Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.